Cargando…

Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review

SIMPLE SUMMARY: People with BRCA mutations are at high risk for ovarian and breast cancer. In order to greatly reduce their risks of these cancers, people with BRCA mutations undergo surgery between the ages of 35–45 to remove both ovaries and fallopian tubes. However, this type of surgery results i...

Descripción completa

Detalles Bibliográficos
Autores principales: Nitschke, Amanda S., do Valle, Helena Abreu, Dawson, Lesa, Kwon, Janice S., Hanley, Gillian E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913268/
https://www.ncbi.nlm.nih.gov/pubmed/36765666
http://dx.doi.org/10.3390/cancers15030711
_version_ 1784885384109359104
author Nitschke, Amanda S.
do Valle, Helena Abreu
Dawson, Lesa
Kwon, Janice S.
Hanley, Gillian E.
author_facet Nitschke, Amanda S.
do Valle, Helena Abreu
Dawson, Lesa
Kwon, Janice S.
Hanley, Gillian E.
author_sort Nitschke, Amanda S.
collection PubMed
description SIMPLE SUMMARY: People with BRCA mutations are at high risk for ovarian and breast cancer. In order to greatly reduce their risks of these cancers, people with BRCA mutations undergo surgery between the ages of 35–45 to remove both ovaries and fallopian tubes. However, this type of surgery results in early menopause, which leads to negative long-term health effects. Little is known about these health effects in people with BRCA mutations. In addition, uncertainty surrounds the safety and effectiveness of hormone replacement therapy to treat these health effects and improve quality of life. This review summarizes the current research on the long-term health consequences of early surgical menopause in people with BRCA mutations and highlights the existing research in support of hormone replacement therapy use in this population. ABSTRACT: Risk-reducing bilateral salpingo-oophorectomy (RRBSO) is the gold standard preventative option for BRCA mutation carriers at high risk for ovarian and breast cancer. However, when performed at the recommended ages of 35–45 years, RRBSO induces immediate premature surgical menopause, along with the accompanying adverse psychosocial, cardiovascular, bone, and cognitive health consequences. While these health consequences have been thoroughly studied in the general population, little is known about the long-term health outcomes in the BRCA population. Hormone replacement therapy (HRT) until the average age of natural menopause can help mitigate these health risks, yet the initiation of HRT is a complex decision among BRCA carriers due to concern of increasing the already high risk of breast cancer in these people. This review summarizes the current research on long-term non-cancer risks in BRCA carriers following RRBSO-induced premature surgical menopause, and highlights the existing evidence in support of HRT use in this population.
format Online
Article
Text
id pubmed-9913268
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99132682023-02-11 Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review Nitschke, Amanda S. do Valle, Helena Abreu Dawson, Lesa Kwon, Janice S. Hanley, Gillian E. Cancers (Basel) Review SIMPLE SUMMARY: People with BRCA mutations are at high risk for ovarian and breast cancer. In order to greatly reduce their risks of these cancers, people with BRCA mutations undergo surgery between the ages of 35–45 to remove both ovaries and fallopian tubes. However, this type of surgery results in early menopause, which leads to negative long-term health effects. Little is known about these health effects in people with BRCA mutations. In addition, uncertainty surrounds the safety and effectiveness of hormone replacement therapy to treat these health effects and improve quality of life. This review summarizes the current research on the long-term health consequences of early surgical menopause in people with BRCA mutations and highlights the existing research in support of hormone replacement therapy use in this population. ABSTRACT: Risk-reducing bilateral salpingo-oophorectomy (RRBSO) is the gold standard preventative option for BRCA mutation carriers at high risk for ovarian and breast cancer. However, when performed at the recommended ages of 35–45 years, RRBSO induces immediate premature surgical menopause, along with the accompanying adverse psychosocial, cardiovascular, bone, and cognitive health consequences. While these health consequences have been thoroughly studied in the general population, little is known about the long-term health outcomes in the BRCA population. Hormone replacement therapy (HRT) until the average age of natural menopause can help mitigate these health risks, yet the initiation of HRT is a complex decision among BRCA carriers due to concern of increasing the already high risk of breast cancer in these people. This review summarizes the current research on long-term non-cancer risks in BRCA carriers following RRBSO-induced premature surgical menopause, and highlights the existing evidence in support of HRT use in this population. MDPI 2023-01-24 /pmc/articles/PMC9913268/ /pubmed/36765666 http://dx.doi.org/10.3390/cancers15030711 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nitschke, Amanda S.
do Valle, Helena Abreu
Dawson, Lesa
Kwon, Janice S.
Hanley, Gillian E.
Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review
title Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review
title_full Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review
title_fullStr Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review
title_full_unstemmed Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review
title_short Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review
title_sort long-term non-cancer risks in people with brca mutations following risk-reducing bilateral salpingo-oophorectomy and the role of hormone replacement therapy: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913268/
https://www.ncbi.nlm.nih.gov/pubmed/36765666
http://dx.doi.org/10.3390/cancers15030711
work_keys_str_mv AT nitschkeamandas longtermnoncancerrisksinpeoplewithbrcamutationsfollowingriskreducingbilateralsalpingooophorectomyandtheroleofhormonereplacementtherapyareview
AT dovallehelenaabreu longtermnoncancerrisksinpeoplewithbrcamutationsfollowingriskreducingbilateralsalpingooophorectomyandtheroleofhormonereplacementtherapyareview
AT dawsonlesa longtermnoncancerrisksinpeoplewithbrcamutationsfollowingriskreducingbilateralsalpingooophorectomyandtheroleofhormonereplacementtherapyareview
AT kwonjanices longtermnoncancerrisksinpeoplewithbrcamutationsfollowingriskreducingbilateralsalpingooophorectomyandtheroleofhormonereplacementtherapyareview
AT hanleygilliane longtermnoncancerrisksinpeoplewithbrcamutationsfollowingriskreducingbilateralsalpingooophorectomyandtheroleofhormonereplacementtherapyareview